Range Cancer Therapeutics ETF (CNCR)

9.02
0.00 (0.00%)
Inactive · Last trade price on May 27, 2025
Assets$6.95M
Expense Ratio0.79%
PE Ration/a
Shares Out780,814
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend Daten/a
Payout Frequencyn/a
Payout Ration/a
Volume3,077
Open9.41
Previous Closen/a
Day's Range9.02 - 9.41
52-Week Low7.88
52-Week High16.27
Beta0.95
Holdings2
Inception DateOct 13, 2015

About CNCR

The Range Cancer Therapeutics ETF (CNCR) is an exchange-traded fund that is based on the Range Oncology Therapeutics index. The fund tracks an equal-weighted index of companies currently developing oncology drugs or selling cancer therapeutic products. CNCR was launched on Oct 13, 2015 and is issued by Range.

Asset Class Equity
Category Health
Stock Exchange NASDAQ
Ticker Symbol CNCR
ETF Provider Range
Index Tracked Range Oncology Therapeutics Index

Top Holdings

NameSymbolWeight
US DOLLARSn/a99.94%
DEPOSITS WITH BROKER FOR SHORT POSITIONSn/a0.06%

Performance

CNCR had a total return of -38.26% in the past year, including dividends. Since the fund's inception, the average annual return has been -9.43%.

News

EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION

OKLAHOMA CITY , Oct. 23, 2023 /PRNewswire/ -- Exchange Traded Concepts, LLC, adviser to the Range Cancer Therapeutics ETF (CNCR) and the Loncar China BioPharma ETF (CHNA) is pleased to announce the co...

2 years ago - PRNewsWire

Should Investors Follow Private Equity into Life Sciences?

Reflecting what it considers the vast potential of life sciences companies, Bain Capital is making another huge bet on the industry. The Boston-based investment firm has raised $1.9 billion in a new f...

Other symbols: BBCBNTXPFE
5 years ago - GuruFocus

9 Best Biotech ETFs to Play High-Octane Trends

Biotechnology is a dynamic but often volatile industry. These biotech ETFs provide a lower-risk way to invest in the space.

5 years ago - Kiplinger

Biotech ETFs extend January gains

Biotech exchange-traded funds rallied Monday as investors continued to monitor the sector and its impact on the coronavirus pandemic. The ETFMG Treatments Testing and Advancement ETF gained 4.6% mid-m...

Other symbols: XBI
5 years ago - Market Watch

Specialty biotech funds jump on promising coronavirus, funding news

Specialized health-care exchange-traded funds outperformed the broader stock market Wednesday even as stocks rebounded from a sell-off that left the Nasdaq Composite Index in correction territory. Th...

Other symbols: PTH
6 years ago - Market Watch

6 Best Biotech ETFs to Buy for Cutting-Edge Growth

Biotech ETFs are, in a word, hot.

Other symbols: IBBPBEXBI
6 years ago - Kiplinger

3 ETFs For More Moderna Bets

Shares of biotechnology company Moderna Inc (NASDAQ: MRNA) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress.

Other symbols: IDNA
6 years ago - Benzinga